Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 6/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.43 |
| ▸ | CRACR2A | Q9BSW2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4114887 | 0.90 | NPC1 (0.41) | ROCK2NPC1RAB9AKDM4EMEN1 | |
| SCHEMBL3407111 | 0.83 | KDM4E (0.47) | ROCK2NPC1RAB9AKDM4EMEN1 | |
| SCHEMBL4111354 | 0.83 | NAMPT (0.42) | NPC1RAB9ATRPV1 | |
| SCHEMBL4099205 | 0.81 | TRPV1 (0.44) | NPC1RAB9AKDM4EMEN1KMT2A | |
| SCHEMBL3413449 | 0.79 | TRPV1 (0.42) | L3MBTL1TRPV1 | |
| SCHEMBL4117870 | 0.78 | ATM (0.49) | NPC1KDM4EMEN1KMT2AMAPT | |
| SCHEMBL3413266 | 0.77 | TRPV1 (0.45) | NPC1RAB9AKMT2ATRPV1 | |
| SCHEMBL3411341 | 0.76 | USP2 (0.40) | NPY5RKMT2ATRPV1PARP1 | |
| SCHEMBL3401343 | 0.75 | KMT2A (0.56) | NPC1RAB9AMEN1KMT2AMAPT | |
| SCHEMBL3398554 | 0.75 | NPC1 (0.52) | NPC1RAB9AMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188284-B2 | 2-aminoquinolines | HOFFMAN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | claimed |
| US-20090227583-A1 | 2-AMINOQUINOLINES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2009-09-10 | — | — | US | claimed |
| US-8188284-B2 | 2-aminoquinolines | HOFFMAN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090227583-A1 | 2-AMINOQUINOLINES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227583-A1 | 2-AMINOQUINOLINES | HTR5A, HTR2C, HTR2B | NPY5R 10/4885ROCK2 2131/4885CRACR2A 4065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.